Trenbolone or Boldenone: What's the Difference

Trenbolone and boldenone are often mentioned together, because both came into sport from veterinary medicine and both are administered by injection in the form of esters. The similarity mostly ends there: the molecules have different structures, interact differently with receptors and enzymes, and therefore have different risk profiles. The editorial team examined the key differences at the pharmacological level.

Origins: two veterinary stories

Boldenone (1-dehydrotestosterone) has been known to pharmacologists since the mid-20th century. Its undecylenate ester, under trade names such as Equipoise, was used in veterinary medicine, primarily for horses, to improve appetite, weight gain, and the general condition of animals after wasting. For humans, boldenone was never registered as a medicinal product in most countries.

Trenbolone has a different fate. Trenbolone acetate was and is used in animal husbandry in the form of subcutaneous implants for cattle: it accelerates the gain of muscle mass and improves feed conversion efficiency. It was precisely the economic efficiency in cattle raising, not medical indications, that determined its wide production.

For a short period trenbolone also existed as a drug for humans: in France its hexahydrobenzylcarbonate was produced under the name Parabolan, later discontinued. Today no trenbolone product is registered for treating humans in the leading jurisdictions.

So both boldenone and trenbolone circulating in the sports environment come either from veterinary sources or from illegal production. This in itself means an absence of the quality control, sterility, and precise dosing inherent in pharmaceutical products for humans.

An important consequence of the veterinary origin: there are almost no human safety clinical studies for either substance. Most knowledge comes from animal experiments, pharmacological models, and descriptions of individual clinical cases, so any "proven in practice" claims should be treated with caution.

Chemical structure and esters

Boldenone is testosterone with one additional double bond between the first and second carbon atoms in ring A. This minor modification makes the molecule structurally very close to methandienone, from which boldenone differs only in the absence of the 17α-methyl group. This is precisely why boldenone is not an oral drug and does not have the marked liver toxicity characteristic of 17α-alkylated steroids.

Trenbolone belongs to the derivatives of 19-nortestosterone (like nandrolone) but has three conjugated double bonds - at positions 4, 9, and 11. This system of bonds makes the molecule more rigid and changes its affinity for receptors. The review by Yarrow and co-authors (2010) emphasizes that trenbolone binds to the androgen receptor with very high affinity.

Both substances in circulation most often exist in the form of esters. For boldenone the typical one is the long undecylenate, which provides slow release from an oil depot. Trenbolone is found mainly as acetate (a short ester) and enanthate; the ester determines only the rate of release, not the properties of the molecule itself.

The table below summarizes the basic structural differences of the two compounds.

The structural difference also explains the differences in metabolism. Boldenone is partly converted by the body's enzymes into other androgens and estrogens, whereas trenbolone largely remains in its active form, not undergoing aromatization and not being potentiated via 5α-reductase.

Mechanism of action: receptors and enzymes

Both substances act as androgen receptor agonists: by binding to it, they trigger the transcription of genes responsible for protein synthesis in muscle tissue. However, the strength and "breadth" of this action differ. According to experimental work, trenbolone shows a much higher affinity for the androgen receptor than testosterone, whereas boldenone is closer to the parent testosterone on this parameter.

The second difference is the interaction with aromatase. Boldenone is a substrate of this enzyme and can be converted into an estrogenic compound, though, as pharmacological reviews note, more slowly than testosterone. Trenbolone practically does not undergo aromatization, so classic estrogenic effects are less typical for it.

The third difference concerns other steroid receptors. Trenbolone, like nandrolone, binds to the progesterone receptor. Through this mechanism, effects are possible that outwardly resemble estrogenic ones (in particular, on breast tissue), as well as additional suppression of the hypothalamic-pituitary axis.

The fourth is the effect on one's own hormonal system. Any exogenous androgen, by the principle of negative feedback, reduces the secretion of LH and FSH, but for trenbolone, with its high androgenic and progestin activity, this suppression is considered especially pronounced in case descriptions and reviews.

In summary, one can put it this way: boldenone is pharmacologically closer to a "mild" modification of testosterone, whereas trenbolone is a potent synthetic androgen with additional progestin activity. However, the "mildness" of boldenone is relative and does not mean safety.

Side effects: where the difference lies

The basic risks of both substances are common to the entire class of anabolic-androgenic steroids: adverse changes in the lipid profile with a decrease in HDL, elevated blood pressure, myocardial hypertrophy, erythrocytosis, suppression of spermatogenesis, and acne. The systematic review of the Endocrine Society (Pope et al., 2014) treats these consequences as typical of supraphysiological use.

Boldenone's specific "reputation" is associated with a rise in hematocrit. Stimulation of erythropoiesis is characteristic of all androgens, and for boldenone, which is usually used in long courses, it often becomes noticeable. Increased blood viscosity raises the risk of thrombosis, especially in combination with dehydration and high blood pressure.

For trenbolone, user descriptions and individual clinical observations most often feature neuropsychiatric effects: insomnia, irritability, anxiety, aggressiveness. In animal experiments trenbolone was also associated with behavioral changes. In addition, pronounced night sweating and worsened exercise tolerance have been reported.

• Common to both:dyslipidemia, hypertension, suppression of the hormonal axis, infertility, virilization in women.
• More characteristic of boldenone:erythrocytosis, moderate estrogenic effects due to aromatization.
• More characteristic of trenbolone:psychoemotional changes, progestin-mediated effects, deep suppression, sleep disturbances.

Cardiotoxicity deserves a separate mention. The review by Baggish and co-authors (2017) in the journal Circulation summarizes data on reduced myocardial contractile function and accelerated atherosclerosis in long-term users of anabolic steroids. These data concern the class as a whole and do not allow either of the two substances to be called "cardio-safe."

Legal status and doping control

On the WADA Prohibited List, both boldenone and trenbolone belong to class S1 "Anabolic Agents" and are prohibited at all times - both in and out of competition. An athlete in whose sample these substances or their metabolites are found bears responsibility regardless of intent.

For boldenone there is a complication related to the fact that at very low concentrations it can form endogenously or as a result of microbial transformation in the sample. Therefore anti-doping laboratories use special methods, in particular isotope mass spectrometry, to distinguish the exogenous origin of the substance.

Trenbolone does not form endogenously in humans, so its detection, as a rule, unambiguously indicates external intake. At the same time, there are known cases where the possibility of trenbolone entering the body through the meat of implanted animals was discussed in athletes; such arguments are considered individually by anti-doping bodies.

From a legal standpoint, in many countries the circulation of anabolic steroids without a prescription is governed by medicines legislation, and in some by criminal law. The veterinary origin of a drug does not make it legal for human use.

Another aspect is quality. Studies of illegal-market products have repeatedly revealed non-compliance with the declared composition: other substances, incorrect concentration, microbial contamination. For veterinary products, the sterility risks of injecting into a human are especially high.

Editorial conclusions

Boldenone is a weakly modified testosterone, capable of aromatization and with a relatively moderate affinity for the androgen receptor. Trenbolone is a potent derivative of 19-nortestosterone that does not aromatize but also acts through the progesterone receptor.

These differences explain the different emphases in the side-effect profile: for boldenone - blood changes and moderate estrogenic effects; for trenbolone - psychoemotional disturbances, deep suppression of the hormonal axis, and progestin reactions. What they have in common are the cardiovascular risks and the threat to fertility.

Neither substance has undergone full-fledged clinical trials in humans, both are banned by WADA, and the products circulating on the market are mostly veterinary or illegal ones of unknown quality.

If this topic interests you, we also recommend reading our materials "Trenbolone vs Boldenone: Which to Choose and for Whom," on controlling hematocrit, and on restoring the hormonal system after anabolic steroids.

References

1. Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010;75(6):377–389.
2. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
3. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
4. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
5. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42(7):1001–1020.
6. World Anti-Doping Agency. The World Anti-Doping Code: International Standard — Prohibited List. Montreal: WADA; актуальна редакція.
7. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.